NCT05277727 is a NA clinical trial of Fucoidan 500mg in Inflammatory Response, sponsored by Marinova Pty Ltd.

Who is sponsoring NCT05277727?

NCT05277727 is sponsored by Marinova Pty Ltd.

What drugs are being tested in NCT05277727?

Interventions in NCT05277727: Fucoidan 500mg, Placebo.

What condition does NCT05277727 study?

NCT05277727 studies Inflammatory Response.

Is NCT05277727 still recruiting?

NCT05277727 is currently completed. Last updated 12 July 2022.

Last reviewed 2022-07-12 · How we verify

NCT05277727

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inflammatory and Immune Response After High Intensity Exercise

Completed NA Last updated 12 July 2022

What this trial tests

NA trial testing Fucoidan 500mg in Inflammatory Response in 16 participants. Completed in 30 June 2022.

Timeline

5 January 2022

Primary endpoint
4 March 2022

30 June 2022

Quick facts

Lead sponsor	Marinova Pty Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	supportive care
Enrollment	16
Start date	5 January 2022
Primary completion	4 March 2022
Estimated completion	30 June 2022
Sites	1 location across United States

Drugs / interventions tested

Fucoidan 500mg
Placebo

Conditions studied

Inflammatory Response — all drugs for Inflammatory Response →

Sponsor

Marinova Pty Ltd

Who can join

Adults 18 to 40, any sex, with Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double-blinded, randomized, placebo-controlled, cross-over study is designed to evaluate the potential effects of a fucoidan supplement on the inflammatory and immune responses following high intensity exercise.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Inflammatory Response

Currently open trials in the same condition.

NCT06450704 — Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders · NA · recruiting
NCT06519487 — Social Experiences and Demographic Factors in the Regulation of Immune Cells · NA · recruiting
NCT06434701 — Severe COVID-19 Infection in Children Presenting to EDs in Israel and England · NA · recruiting
NCT06491966 — Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis · recruiting
NCT06342024 — Pistachio Consumption on Inflammatory Markers and Lean Body Mass · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05277727 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marinova Pty Ltd
Last refreshed: 12 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05277727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing